Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism

Hiroshi Watanabe, Ryusei Sugimoto, Komei Ikegami, Yuki Enoki, Tadashi Imafuku, Rui Fujimura, Jing Bi, Kento Nishida, Yoshiaki Sakaguchi, Michiya Murata, Hitoshi Maeda, Kenshiro Hirata, Sachiko Jingami, Yu Ishima, Motoko Tanaka, Kazutaka Matsushita, Hirotaka Komaba, Masafumi Fukagawa, Masaki Otagiri, Toru Maruyama

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Chronic kidney disease (CKD), which affects, not only renal clearance, but also non-renal clearance, is accompanied by a decline in renal function. Although it has been suggested that humoral factors, such as uremic toxins that accumulate in the body under CKD conditions, could be involved in the changes associated with non-renal drug clearance, the overall process is not completely understood. In this study, we report on the role of parathyroid hormone (PTH), a middle molecule uremic toxin, on the expression of drug metabolizing or transporting proteins using rats with secondary hyperparathyroidism (SHPT) as models. In SHPT rats, hepatic and intestinal CYP3A expression was suppressed, but the changes were recovered by the administration of the calcimimetic cinacalcet, a PTH suppressor. Under the same experimental conditions, a pharmacokinetic study using orally administered midazolam, a substrate for CYP3A, showed that the AUC was increased by 5 times in SHPT rats, but that was partially recovered by a cinacalcet treatment. This was directly tested in rat primary hepatocytes and intestinal Caco-2 cells where the expression of the CYP3A protein was down-regulated by PTH (1–34). In Caco-2 cells, PTH (1–34) down-regulated the expression of CYP3A mRNA, but an inactive PTH derivative (13–34) had no effect. 8-Bromo-cyclic adenosine monophosphate, a membrane-permeable cAMP analog, reduced mRNA expression of CYP3A whereas the inhibitors of PI3K, NF-κB, PKC and PKA reversed the PTH-induced CYP3A down-regulation. These results suggest that PTH down-regulates CYP3A through multiple signaling pathways, including the PI3K/PKC/PKA/NF-κB pathway after the elevation of intracellular cAMP, and the effect of PTH can be prevented by cinacalcet treatment.

Original languageEnglish
Pages (from-to)192-201
Number of pages10
JournalBiochemical Pharmacology
Volume145
DOIs
Publication statusPublished - 2017 Dec 1
Externally publishedYes

Fingerprint

Cytochrome P-450 CYP3A
Secondary Hyperparathyroidism
Parathyroid Hormone
Phosphatidylinositol 3-Kinases
Down-Regulation
Rats
Caco-2 Cells
Chronic Renal Insufficiency
8-Bromo Cyclic Adenosine Monophosphate
Kidney
Messenger RNA
Pharmacokinetics
Midazolam
Pharmaceutical Preparations
Area Under Curve
Hepatocytes
Proteins
Derivatives
Membranes
Liver

Keywords

  • Chronic kidney disease
  • Cinacalcet
  • Cytochrome P450 3A
  • Parathyroid hormone
  • Secondary hyperparathyroidism

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism. / Watanabe, Hiroshi; Sugimoto, Ryusei; Ikegami, Komei; Enoki, Yuki; Imafuku, Tadashi; Fujimura, Rui; Bi, Jing; Nishida, Kento; Sakaguchi, Yoshiaki; Murata, Michiya; Maeda, Hitoshi; Hirata, Kenshiro; Jingami, Sachiko; Ishima, Yu; Tanaka, Motoko; Matsushita, Kazutaka; Komaba, Hirotaka; Fukagawa, Masafumi; Otagiri, Masaki; Maruyama, Toru.

In: Biochemical Pharmacology, Vol. 145, 01.12.2017, p. 192-201.

Research output: Contribution to journalArticle

Watanabe, H, Sugimoto, R, Ikegami, K, Enoki, Y, Imafuku, T, Fujimura, R, Bi, J, Nishida, K, Sakaguchi, Y, Murata, M, Maeda, H, Hirata, K, Jingami, S, Ishima, Y, Tanaka, M, Matsushita, K, Komaba, H, Fukagawa, M, Otagiri, M & Maruyama, T 2017, 'Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism', Biochemical Pharmacology, vol. 145, pp. 192-201. https://doi.org/10.1016/j.bcp.2017.08.016
Watanabe, Hiroshi ; Sugimoto, Ryusei ; Ikegami, Komei ; Enoki, Yuki ; Imafuku, Tadashi ; Fujimura, Rui ; Bi, Jing ; Nishida, Kento ; Sakaguchi, Yoshiaki ; Murata, Michiya ; Maeda, Hitoshi ; Hirata, Kenshiro ; Jingami, Sachiko ; Ishima, Yu ; Tanaka, Motoko ; Matsushita, Kazutaka ; Komaba, Hirotaka ; Fukagawa, Masafumi ; Otagiri, Masaki ; Maruyama, Toru. / Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism. In: Biochemical Pharmacology. 2017 ; Vol. 145. pp. 192-201.
@article{8d07f5c78ec0441ab15ad8fc53c9a5d3,
title = "Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism",
abstract = "Chronic kidney disease (CKD), which affects, not only renal clearance, but also non-renal clearance, is accompanied by a decline in renal function. Although it has been suggested that humoral factors, such as uremic toxins that accumulate in the body under CKD conditions, could be involved in the changes associated with non-renal drug clearance, the overall process is not completely understood. In this study, we report on the role of parathyroid hormone (PTH), a middle molecule uremic toxin, on the expression of drug metabolizing or transporting proteins using rats with secondary hyperparathyroidism (SHPT) as models. In SHPT rats, hepatic and intestinal CYP3A expression was suppressed, but the changes were recovered by the administration of the calcimimetic cinacalcet, a PTH suppressor. Under the same experimental conditions, a pharmacokinetic study using orally administered midazolam, a substrate for CYP3A, showed that the AUC was increased by 5 times in SHPT rats, but that was partially recovered by a cinacalcet treatment. This was directly tested in rat primary hepatocytes and intestinal Caco-2 cells where the expression of the CYP3A protein was down-regulated by PTH (1–34). In Caco-2 cells, PTH (1–34) down-regulated the expression of CYP3A mRNA, but an inactive PTH derivative (13–34) had no effect. 8-Bromo-cyclic adenosine monophosphate, a membrane-permeable cAMP analog, reduced mRNA expression of CYP3A whereas the inhibitors of PI3K, NF-κB, PKC and PKA reversed the PTH-induced CYP3A down-regulation. These results suggest that PTH down-regulates CYP3A through multiple signaling pathways, including the PI3K/PKC/PKA/NF-κB pathway after the elevation of intracellular cAMP, and the effect of PTH can be prevented by cinacalcet treatment.",
keywords = "Chronic kidney disease, Cinacalcet, Cytochrome P450 3A, Parathyroid hormone, Secondary hyperparathyroidism",
author = "Hiroshi Watanabe and Ryusei Sugimoto and Komei Ikegami and Yuki Enoki and Tadashi Imafuku and Rui Fujimura and Jing Bi and Kento Nishida and Yoshiaki Sakaguchi and Michiya Murata and Hitoshi Maeda and Kenshiro Hirata and Sachiko Jingami and Yu Ishima and Motoko Tanaka and Kazutaka Matsushita and Hirotaka Komaba and Masafumi Fukagawa and Masaki Otagiri and Toru Maruyama",
year = "2017",
month = "12",
day = "1",
doi = "10.1016/j.bcp.2017.08.016",
language = "English",
volume = "145",
pages = "192--201",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Parathyroid hormone contributes to the down-regulation of cytochrome P450 3A through the cAMP/PI3K/PKC/PKA/NF-κB signaling pathway in secondary hyperparathyroidism

AU - Watanabe, Hiroshi

AU - Sugimoto, Ryusei

AU - Ikegami, Komei

AU - Enoki, Yuki

AU - Imafuku, Tadashi

AU - Fujimura, Rui

AU - Bi, Jing

AU - Nishida, Kento

AU - Sakaguchi, Yoshiaki

AU - Murata, Michiya

AU - Maeda, Hitoshi

AU - Hirata, Kenshiro

AU - Jingami, Sachiko

AU - Ishima, Yu

AU - Tanaka, Motoko

AU - Matsushita, Kazutaka

AU - Komaba, Hirotaka

AU - Fukagawa, Masafumi

AU - Otagiri, Masaki

AU - Maruyama, Toru

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Chronic kidney disease (CKD), which affects, not only renal clearance, but also non-renal clearance, is accompanied by a decline in renal function. Although it has been suggested that humoral factors, such as uremic toxins that accumulate in the body under CKD conditions, could be involved in the changes associated with non-renal drug clearance, the overall process is not completely understood. In this study, we report on the role of parathyroid hormone (PTH), a middle molecule uremic toxin, on the expression of drug metabolizing or transporting proteins using rats with secondary hyperparathyroidism (SHPT) as models. In SHPT rats, hepatic and intestinal CYP3A expression was suppressed, but the changes were recovered by the administration of the calcimimetic cinacalcet, a PTH suppressor. Under the same experimental conditions, a pharmacokinetic study using orally administered midazolam, a substrate for CYP3A, showed that the AUC was increased by 5 times in SHPT rats, but that was partially recovered by a cinacalcet treatment. This was directly tested in rat primary hepatocytes and intestinal Caco-2 cells where the expression of the CYP3A protein was down-regulated by PTH (1–34). In Caco-2 cells, PTH (1–34) down-regulated the expression of CYP3A mRNA, but an inactive PTH derivative (13–34) had no effect. 8-Bromo-cyclic adenosine monophosphate, a membrane-permeable cAMP analog, reduced mRNA expression of CYP3A whereas the inhibitors of PI3K, NF-κB, PKC and PKA reversed the PTH-induced CYP3A down-regulation. These results suggest that PTH down-regulates CYP3A through multiple signaling pathways, including the PI3K/PKC/PKA/NF-κB pathway after the elevation of intracellular cAMP, and the effect of PTH can be prevented by cinacalcet treatment.

AB - Chronic kidney disease (CKD), which affects, not only renal clearance, but also non-renal clearance, is accompanied by a decline in renal function. Although it has been suggested that humoral factors, such as uremic toxins that accumulate in the body under CKD conditions, could be involved in the changes associated with non-renal drug clearance, the overall process is not completely understood. In this study, we report on the role of parathyroid hormone (PTH), a middle molecule uremic toxin, on the expression of drug metabolizing or transporting proteins using rats with secondary hyperparathyroidism (SHPT) as models. In SHPT rats, hepatic and intestinal CYP3A expression was suppressed, but the changes were recovered by the administration of the calcimimetic cinacalcet, a PTH suppressor. Under the same experimental conditions, a pharmacokinetic study using orally administered midazolam, a substrate for CYP3A, showed that the AUC was increased by 5 times in SHPT rats, but that was partially recovered by a cinacalcet treatment. This was directly tested in rat primary hepatocytes and intestinal Caco-2 cells where the expression of the CYP3A protein was down-regulated by PTH (1–34). In Caco-2 cells, PTH (1–34) down-regulated the expression of CYP3A mRNA, but an inactive PTH derivative (13–34) had no effect. 8-Bromo-cyclic adenosine monophosphate, a membrane-permeable cAMP analog, reduced mRNA expression of CYP3A whereas the inhibitors of PI3K, NF-κB, PKC and PKA reversed the PTH-induced CYP3A down-regulation. These results suggest that PTH down-regulates CYP3A through multiple signaling pathways, including the PI3K/PKC/PKA/NF-κB pathway after the elevation of intracellular cAMP, and the effect of PTH can be prevented by cinacalcet treatment.

KW - Chronic kidney disease

KW - Cinacalcet

KW - Cytochrome P450 3A

KW - Parathyroid hormone

KW - Secondary hyperparathyroidism

UR - http://www.scopus.com/inward/record.url?scp=85028595242&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028595242&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2017.08.016

DO - 10.1016/j.bcp.2017.08.016

M3 - Article

C2 - 28843775

AN - SCOPUS:85028595242

VL - 145

SP - 192

EP - 201

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -